A new trading day began on Monday, with UroGen Pharma Ltd (NASDAQ: URGN) stock price up 14.08% from the previous day of trading, before settling in for the closing price of $9.87. URGN’s price has ranged from $8.94 to $20.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 13165.79% over the past five years. Meanwhile, its annual earnings per share averaged 1.29%. With a float of $38.22 million, this company’s outstanding shares have now reached $42.23 million.
Let’s look at the performance matrix of the company that is accounted for 235 employees. In terms of profitability, gross margin is 90.18%, operating margin of -107.06%, and the pretax margin is -137.22%.
UroGen Pharma Ltd (URGN) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of UroGen Pharma Ltd is 17.09%, while institutional ownership is 80.50%. The most recent insider transaction that took place on Jan 31 ’25, was worth 50,698. In this transaction Chief Medical Officer of this company sold 4,551 shares at a rate of $11.14, taking the stock ownership to the 145,666 shares. Before that another transaction happened on Jan 31 ’25, when Company’s General Counsel sold 7,379 for $11.14, making the entire transaction worth $82,202. This insider now owns 26,468 shares in total.
UroGen Pharma Ltd (URGN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 1.29% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
Here are UroGen Pharma Ltd’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.22, a number that is poised to hit -0.80 in the next quarter and is forecasted to reach -0.80 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
UroGen Pharma Ltd (NASDAQ: URGN) saw its 5-day average volume 0.94 million, a positive change from its year-to-date volume of 0.44 million. As of the previous 9 days, the stock’s Stochastic %D was 57.38%. Additionally, its Average True Range was 0.73.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 55.33%, which indicates a significant decrease from 84.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.97% in the past 14 days, which was higher than the 53.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.49, while its 200-day Moving Average is $12.19. Nevertheless, the first resistance level for the watch stands at $11.94 in the near term. At $12.63, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.57. If the price goes on to break the first support level at $10.31, it is likely to go to the next support level at $9.37. Assuming the price breaks the second support level, the third support level stands at $8.68.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
With a market capitalization of 519.02 million, the company has a total of 46,094K Shares Outstanding. Currently, annual sales are 90,400 K while annual income is -126,870 K. The company’s previous quarter sales were 24,570 K while its latest quarter income was -37,510 K.
